Table 1 Comparison of the clinicopathological parameters of patients among the three groups at baseline

n

381 (53.2%)

161 (22.5%)

174 (24.3%)

Male, n (%)

193 (50.7%)

92 (57.1%)

109 (62.6%)^†

Age (years)

49 ± 14

48 ± 15

52 ± 14^†§

Age ≥ 60,n(%)

91 (23.9%)

40 (24.8%)

57 (32.8%)

SBP (mm Hg)

130 (119,147)

136 (123,154)^*

147 (132,162)^†§

DBP (mm Hg)

80 (72,88)

80 (74,91)

86 (77,95)^†§

Hypertension, n (%)

158 (41.5%)

86 (53.4%)

118 (67.8%)^†§

Duration of disease before biopsy (months)

2 (1,5)

2 (1,7)

4 (1,9) ^†

Albumin(g/L)

24.4 (20.7,28.9)

21.7 (18.5,26.9)^*

20.9 (17.0,24.4)^†

Urine protein content(g/24 h)

4.0 (2.3,6.6)

5.4 (3.4,8.1)^*

5.6 (3.6,8.8)^†

Serum creatinine (μmol/L)

72 (59,83)

78 (64,92)^*

85 (69,103)^†§

eGFR (ml/min per 1.73m²)

98 (83,110)

91 (77,109)^*

81 (64,102)^†§

CKD ≥ 3stage

13 (3.4%)

18 (11.2%)

37 (21.3%)^†§

Immunosuppressants

289 (75.9%)

136 (84.4%)

151 (86.8%)^†

Stage

*

†

 I

131 (34.4%)

32 (19.9%)

26 (14.9%)

 II

214 (56.2%)

88 (54.7%)

104 (59.8%)

 III

35 (9.2%)

40 (24.8%)

42 (24.1%)

 IV

1 (0.3%)

1 (0.6%)

2 (1.1%)

Global glomerulosclerosis (%)

0 (0,6.3)

2.3 (0,8.4)

5.8 (0,12.6)^†§

Proliferation of mesangial area

*

†§

 0

191 (50.1%)

58 (36%)

40 (23%)

 1

171 (44.9%)

85 (52.8%)

106 (60.9%)

 2

19 (5%)

17 (10.6%)

25 (14.4%)

 3

0 (0%)

1 (0.6%)

3 (1.7%)

Tubulointerstitial fibrosis(%)

2 (0,5)

3 (2,8)^*

8 (3,18.5)^†§

Vascular sclerosis

†§

 0

105 (27.6%)

41 (25.5%)

22 (12.6%)

 1

211 (55.4%)

88 (54.7%)

97 (55.7%)

 2

56 (14.7%)

28 (17.4%)

42 (24.1%)

 3

9 (2.4%)

4 (2.5%)

13 (7.5%)